Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Geyer

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Contemporary Clinical Trials Communications|January 22, 2026
Protocol for neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapyUgur Sener, Taylor Galloway, Bryan Neth, et al.
Haematologica|May 22, 2025
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic responseMatthew J Rees, Susan Geyer, Binoy Yohannan, et al.
Vaccine|October 3, 2018
Impact of early life exposure to ionizing radiation on influenza vaccine response in an elderly Japanese cohortTomonori Hayashi, Heather E Lynch, Susan Geyer, et al.
Blood|July 13, 2012
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemiaPearlly Yan, David Frankhouser, Mark Murphy, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineWilliam Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Blood Cancer Journal|May 15, 2023
Conditional survival in multiple myeloma and impact of prognostic factors over timeNadine H Abdallah, Alexandra N Smith, Susan Geyer, et al.
Blood Cancer Journal|December 31, 2025
Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myelomaKenneth J C Lim, Melinda Tan, Ricardo Parrondo, et al.
Blood|May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaWilliam Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
JCI Insight|September 21, 2018
Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetesFederica Vecchio, Nicola Lo Buono, Angela Stabilini, et al.
Haematologica|January 15, 2026
Hepatic response criteria in light chain amyloidosis: a multicenter validation studyEli Muchtar, Giovanni Palladini, Stefan Schonland, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Contemporary Clinical Trials Communications|January 22, 2026
Protocol for neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapyUgur Sener, Taylor Galloway, Bryan Neth, et al.
Haematologica|May 22, 2025
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic responseMatthew J Rees, Susan Geyer, Binoy Yohannan, et al.
Vaccine|October 3, 2018
Impact of early life exposure to ionizing radiation on influenza vaccine response in an elderly Japanese cohortTomonori Hayashi, Heather E Lynch, Susan Geyer, et al.
Blood|July 13, 2012
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemiaPearlly Yan, David Frankhouser, Mark Murphy, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineWilliam Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Blood Cancer Journal|May 15, 2023
Conditional survival in multiple myeloma and impact of prognostic factors over timeNadine H Abdallah, Alexandra N Smith, Susan Geyer, et al.
Blood Cancer Journal|December 31, 2025
Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myelomaKenneth J C Lim, Melinda Tan, Ricardo Parrondo, et al.
Blood|May 9, 2012
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemiaWilliam Blum, Sebastian Schwind, Somayeh S Tarighat, et al.
JCI Insight|September 21, 2018
Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetesFederica Vecchio, Nicola Lo Buono, Angela Stabilini, et al.
Haematologica|January 15, 2026
Hepatic response criteria in light chain amyloidosis: a multicenter validation studyEli Muchtar, Giovanni Palladini, Stefan Schonland, et al.
Pageof 12